Tweets
☝️Treatment is the 3rd reason why we need to order a BL HRCT in pts with ILD; "We can't treat SSc-ILD if we are not able to detect SSc-ILD" - Dr. Elana Bernstein
#ACR @RheumNow #rheumatology https://t.co/ooZVSbt3Xf
sheila @RHEUMarampa ( View Tweet )
3 years 8 months ago
Peresolimab humanized IgG1 mab
➢ stimulates PD-1 & physiological immune inhibitory pathways
➢ In RA phase 2 study, superior to placebo at Week 12 DAS28/CDAI
➢ safety events were similar between treatment groups
Emery P #L03 https://t.co/4Jd79CW5RA #ACR22 #ACRBest @RheumNow https://t.co/PSuLQgjYuz
Dr. Antoni Chan @synovialjoints ( View Tweet )
3 years 8 months ago
BE OPTIMAL Study - Bimekizumab (IL-17A and IL-17F inhibitor) for treatment of PsA.
Similar ACR 50 (~50%) response rates of Bimekizumab, adalimumab, and placebo (switched to BKZ at wk 16).
~60% PASI100 in BKZ
#ACRBest Abs#L02 @RheumNow #ACR22 https://t.co/W2B2kyju9F
Robert B Chao, MD @doctorRBC ( View Tweet )
3 years 8 months ago
Hamroun et al. Preconceptual NSAID use assoc impaired fertility in SpA, HR 3.01 for time-to-conception @RheumNow #ACR22 Abstr#1673 https://t.co/jresR9MfXF https://t.co/flyfJob9un
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Congratulations @RheumNow @rheum_cat @CreakyJoints 🎉 #ACR22 https://t.co/P7iLUPnt0p
Catherine Sims, MD @DrCassySims ( View Tweet )
3 years 8 months ago
Ab1674 #ACR22 HCQ in pregnancy is SAFE and Standard of Care!
In Utero Exposure to HCQ does NOT ass w/ ocular toxicity: OCTs 5 yrs after birth 👀
PATCH study of HCQ to reduce CHB in pregnancy
18% CHB (historical) -> 7% treated risk
OCT: retinal thickness nml at 5 yrs
@RheumNow
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
#CurbsideConsult. What would you do? 45 yo female with dSSc and ILD, had been on stable MMF 1500 mg bid. she had increased SOB, new dry cough, hand pain, stiffness.Exam noted synovitis, Labs: ESR 76, Echo RSVP 25 mmHg, HRCT increased ILD compared to a year ago. #ACR22 @rheumnow
TheDaoIndex @KDAO2011 ( View Tweet )
3 years 8 months ago
Are TNFi or IL-6Ri safe in rheumatic irAEs from ICI Rx?
Multiple big US centers retrospective:
TNFi, IL-6Ri vs MTX
p>0.05, but may be approx 2x risk of cancer progression
Has made me more cautious about TNFi, IL-6Ri - use MTX when you can
Lovely work! ABST1669 #ACR22 @RheumNow https://t.co/cfAT1pQZ7I
David Liew @drdavidliew ( View Tweet )
3 years 8 months ago
This is how Dr. Berstein manages SSc-ILD #ACR22 @rheumnow #CurbsideConsult https://t.co/vP7m0WpdK6
TheDaoIndex @KDAO2011 ( View Tweet )
3 years 8 months ago
Abdel-Wahab et al. TCZ in combo with ipilimumab/nivolumab. Very preliminary results of what will be important trial. Appears safe and well-tolerated with no increased risk cancer progression. @RheumNow #ACR22 Abstr#1670 https://t.co/uPBnHJ9BRH
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Messier et al. WE-CAN pragmatic trial of diet and exercise (vs attention control) in knee OA with high BMI. Significant improvement in pain, walk distance, SF-36 with corresponding reduction in body weight @RheumNow #ACR22 Abstr#1675 https://t.co/uSSzx4u2sp https://t.co/upnIVecRjv
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
SAPHYR results: SAR + 14 wk GC taper showed efficacy vs comparator arm in steroid refractory PMR, including clinically meaningful improvement in QoL. No new safety signals. Plenary Abs 1676 #ACR22 @RheumNow https://t.co/mHu3e9JbCp https://t.co/93kbczSTfS
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
